TG Therapeutics Inc. (TGTX) exhibits 83.7% gross margins and 12.0% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 73.3x enterprise multiple and 4.8% implied options volatility.
Sustained 83.7% gross profitability converts into 20.0% operating margin and 12.0% ROIC, outpacing sector cost of capital.
ROIC: 12.0% // GM: 83.7%YoY revenue trajectory of +87.3% paired with -0.28% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +87.3% // FCF YLD: -0.28%Altman Z-Score of 12.92 and Piotroski F-Score of 6/9 indicate low near-term refinancing stress.
ALTMAN Z: 12.92 // F-SCORE: 6/9Trading at 19.9x trailing P/E (16.7x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 19.9x // EV/EBITDA: 73.3xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $59.95 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 68.0% net margins.
NET MARGIN: 68.0% // D/E: 0.38x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for TGTX & activate live FRED threshold breach alerts.